KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Payables: 2010-2024

Historic Payables for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $60.9 million.

  • Emergent BioSolutions' Payables fell 30.76% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.1 million, marking a year-over-year decrease of 85.70%. This contributed to the annual value of $60.9 million for FY2024, which is 88.42% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Payables of $60.9 million as of FY2024, which was down 88.42% from $525.9 million recorded in FY2023.
  • Emergent BioSolutions' Payables' 5-year high stood at $1.1 billion during FY2022, with a 5-year trough of $60.9 million in FY2024.
  • Moreover, its 3-year median value for Payables was $525.9 million (2023), whereas its average is $549.2 million.
  • Per our database at Business Quant, Emergent BioSolutions' Payables spiked by 560.93% in 2022 and then tumbled by 88.42% in 2024.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Payables stood at $169.9 million in 2020, then dropped by 5.53% to $160.5 million in 2021, then soared by 560.93% to $1.1 billion in 2022, then plummeted by 50.42% to $525.9 million in 2023, then tumbled by 88.42% to $60.9 million in 2024.